Brief: Creative Medical Technology Holdings, Inc. Advances FDA Cleared Adapt Clinical Trial With Positive Independent Review, Validating The Safety And Potential Of CELZ-201 For Chronic Lower Back Pain Treatment
13/11/2024 14:07
Nov 13 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. ADVANCES FDA
CLEARED
ADAPT CLINICAL TRIAL WITH POSITIVE INDEPENDENT REVIEW,
VALIDATING THE SAFETY AND POTENTIAL OF CELZ-201 FOR CHRONIC
LOWER BACK PAIN TREATMENT
Source text: ID:nGNX1mBkBQ
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM